发布求助
文献互助 智能选刊 最新文献

Vaccination research : open journal最新文献

筛选
英文 中文
The Concept of Developing a Plasmodium vivax Malarial Vaccine with a Focus on its Pre-erythrocytic Stage 间日疟原虫疟疾疫苗的研制构想及其红细胞前阶段的研究
Vaccination research : open journal Pub Date : 2018-12-31 DOI: 10.17140/vroj-3-109
Tuan Imaad Aarif, S. Dias
{"title":"The Concept of Developing a Plasmodium vivax Malarial Vaccine with a Focus on its Pre-erythrocytic Stage","authors":"Tuan Imaad Aarif, S. Dias","doi":"10.17140/vroj-3-109","DOIUrl":"https://doi.org/10.17140/vroj-3-109","url":null,"abstract":"Plasmodium vivax, one of the most prevalent human malarial parasites, continues to cause significant morbidity for hundreds of millions worldwide. Due to increasing drug resistance and vivax specific relapses, immunoprophylaxis signifies a key control strategy in efforts to eradicate malaria worldwide. By far, the circumsporozoite protein (CSP) based vaccines are being developed since the 1980’s. However, they have produced major limitations in eliciting partial immune responses towards the parasite. Nevertheless, the Long Synthetic Peptides (LSP’s) and Vivax Malarial Protein 001 (VMP001) have produced considerable amount of immune responses and are currently undergoing phase 1 clinical trials according to several studies. Recent developments of a Virus-like particle (VLP) was found to be an efficacious vaccine candidate against a human sporozoite challenge model. The VLP’s elicited high antibody titers that remained consistent for a number of days but eventually decreased. In addition, vaccine candidates such as the VLP’s are currently being used to target CSP based–antigens such as the Cell-Traversal Proteins to obstruct hepatocyte invasion by sporozoites. However, substantial humoral and cellular immune responses were not produced to alleviate this process. Further research of these vaccine candidates as well as to analyze its effects towards specific CSP based antigens would immensely contribute to move clinical development forward and to further identify mechanism of immunity.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79319083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Education and Health System Collaboration are Indispensable in Vaccination Coverage 教育和卫生系统的合作对疫苗接种覆盖率是不可或缺的
Vaccination research : open journal Pub Date : 2018-12-31 DOI: 10.17140/vroj-3-e005
Chengjun Sun
{"title":"Education and Health System Collaboration are Indispensable in Vaccination Coverage","authors":"Chengjun Sun","doi":"10.17140/vroj-3-e005","DOIUrl":"https://doi.org/10.17140/vroj-3-e005","url":null,"abstract":"The practice of immunization dates back hundreds of years. Over the 18th and 19th centuries, systematic implementation of mass smallpox immunization culminated in its global eradication in 1979. The 20th century saw great successes at developing vaccines and reducing the burden of infectious diseases such as yellow fever, hepatitis B and influenza.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84405373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Case for Flu Vaccination 接种流感疫苗的理由
Vaccination research : open journal Pub Date : 2018-12-31 DOI: 10.17140/vroj-3-e006
O. Akinlaja
{"title":"The Case for Flu Vaccination","authors":"O. Akinlaja","doi":"10.17140/vroj-3-e006","DOIUrl":"https://doi.org/10.17140/vroj-3-e006","url":null,"abstract":"Influenza or flu vaccine encompasses the seasonal vaccination that protects against infection by the influenza viruses. It’s generally available in two forms; the inactive form administered as shots or intramuscular injections and the weakened live viral forms sprayed intranasally.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78676158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Adenovirus-Vectored Vaccines Development 腺病毒载体疫苗的研究进展
Vaccination research : open journal Pub Date : 2017-12-31 DOI: 10.17140/vroj-2-e004
A. Zakhartchouk
{"title":"Recent Advances in Adenovirus-Vectored Vaccines Development","authors":"A. Zakhartchouk","doi":"10.17140/vroj-2-e004","DOIUrl":"https://doi.org/10.17140/vroj-2-e004","url":null,"abstract":"Recombinant adenovirus-vectored vaccines based on human adenovirus serotype 5 (HAdV-5) have been extensively studied both pre-clinically and in clinical trials for the past 25 years. Initially, they were considered as the most promising platform for human immunodeficiency virus (HIV) vaccine development. However, HAdV-5-based vaccine did not meet expectations in a large-scale clinical trial called STEP trial. In that trial, the vaccine not only showed lack of efficacy, but also suggested an increased trend for HIV acquisition in individuals with pre-existing HAdV-5 neutralizing antibodies.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73855958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ebola Virus: Promising Vaccine Candidates 埃博拉病毒:有希望的候选疫苗
Vaccination research : open journal Pub Date : 2017-12-31 DOI: 10.17140/vroj-2-106
Reema Sameem, S. Dias
{"title":"Ebola Virus: Promising Vaccine Candidates","authors":"Reema Sameem, S. Dias","doi":"10.17140/vroj-2-106","DOIUrl":"https://doi.org/10.17140/vroj-2-106","url":null,"abstract":"Ebola Virus Disease is among the deadliest viral diseases. The field of Ebola vaccine development has progressed over the years with numerous candidates in advanced stages of clinical development. Currently, there is no licensed vaccine against Ebola virus. This review aimed to discuss the promising Ebola vaccine candidates focusing on vaccines against ebola viruses in particular against Zaire ebola virus (ZEBOV). Although DNA vaccines have been evaluated in Phase I clinical studies, it demonstrates low immunogenicity. Thus far, the most successful vaccine platforms are the recombinant viruses including, replicating vesicular stomatitis virus (rVSV) and chimpanzee adenovirus 3 (ChAd3). The successful trials attests that rVSV vaccines will be submitted for licensing in the near future.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86527361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Cell Derived Virus-Like Particles (VLP) in Future Vaccine Development 细胞衍生病毒样颗粒(VLP)在未来疫苗开发中的应用
Vaccination research : open journal Pub Date : 2017-12-31 DOI: 10.17140/vroj-2-e003
P. Walpita
{"title":"Cell Derived Virus-Like Particles (VLP) in Future Vaccine Development","authors":"P. Walpita","doi":"10.17140/vroj-2-e003","DOIUrl":"https://doi.org/10.17140/vroj-2-e003","url":null,"abstract":"Traditionally, viral vaccines have been based on inactivated or live attenuated viruses. While in general, they are highly effective, in some cases they fail to provide adequate immunogenicity, safety or can even cause adverse events. In the case of live attenuated vaccines, achieving a stable optimally attenuated virus is often difficult and there is the potential for reversion. Transmission to the immunocompromised individuals is an additional concern. Inactivated vaccines run the risk of inducing enhanced disease. Single proteins, including single protein nano-particle vaccine attempts have not been successful to date for human use. Various other ways of making vaccines have also been attempted by engineering the virus.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86009198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunobiology of Anticancer Virotherapy With Newcastle Disease Virus in Cancer Patients 新城疫病毒抗癌病毒治疗癌症的免疫生物学研究
Vaccination research : open journal Pub Date : 2017-12-31 DOI: 10.17140/vroj-2-108
S. Farashi-Bonab, N. Khansari
{"title":"Immunobiology of Anticancer Virotherapy With Newcastle Disease Virus in Cancer Patients","authors":"S. Farashi-Bonab, N. Khansari","doi":"10.17140/vroj-2-108","DOIUrl":"https://doi.org/10.17140/vroj-2-108","url":null,"abstract":"Virotherapy with oncolytic viruses that preferentially infect and kill cancer cells is a novel and promising strategy for cancer treatment. Newcastle disease virus (NDV), which is pathogenic in birds, has beneficial clinical effects in cancer patients. NDV virotherapy is safe and elicits an antitumor response in patients affected by different types of cancers. The selective replication of NDV in tumor cells, the lack of genetic recombination, the lack of interaction with host cell DNA, and safety of NDV vaccination in cancer patients has resulted in NDV virotherapy to be accepted as a potentially attractive anticancer modality. However, more knowledge is needed to support the development of optimal NDV-based treatment modality for cancer. In this paper, the biological characteristics of NDV, the clinical effectiveness of NDV-based anticancer vaccination, immunobiology of NDV virotherapy in cancer patients, immune responses to NDV vaccines, and NDV-induced immunogenic cell death and apoptosis of cancer cells have been discussed in detail.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82029273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Fluorinated Lipids Conjugated to Peptide Antigens do not Induce Immune Responses Against Cervical Cancer 与肽抗原结合的氟化脂不会诱导对宫颈癌的免疫反应
Vaccination research : open journal Pub Date : 2017-05-09 DOI: 10.17140/VROJ-1-107
W. M. Hussein, Saori Mukaida, Tzu-yu Liu, I. Toth, M. Skwarczynski
{"title":"Fluorinated Lipids Conjugated to Peptide Antigens do not Induce Immune Responses Against Cervical Cancer","authors":"W. M. Hussein, Saori Mukaida, Tzu-yu Liu, I. Toth, M. Skwarczynski","doi":"10.17140/VROJ-1-107","DOIUrl":"https://doi.org/10.17140/VROJ-1-107","url":null,"abstract":"Background: Despite the high safety profile of peptide-based vaccines over conventional counterparts, the inability of small peptides to produce a strong immune response represents the main obstacle for the development of these types of vaccines. Introducing a self-adjuvanting moiety such as fluorinated lipids can overcome this problem. We have recently demonstrated that fluorinated lipids can induce humoral immune responses against associated peptide antigen; however, the ability of these amphiphilic lipids to elicit a desired cellular immune response to eradicate tumor cells has not been yet investigated. Methods: An in vivo assay was employed to evaluate the ability of fluorinated lipopeptides to eradicate tumor in mouse model. In this study, the double conjugation technique was used to synthesise fluorinated and non-fluorinated lipids conjugated to two cytotoxic T-lymphocyte (CTL) peptide epitopes derived from the E6 and E7 proteins of human papilloma virus (HPV). Results: Mice implanted with TC-1 tumor cells and immunised with fluorinated lipopeptides did not mount a strong cellular immune response, thus did not eradicate the tumors. In contrast, 60% of mice immunised with the non-fluorinated lipopeptide cleared the TC-1 tumor. Conclusion: This result indicated that fluorinated lipids lack of the ability to stimulate a strong cellular immunity despite their ability to elicit significant humoral immune responses.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82274912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Some Problems of Vaccination Campaigns in Developing Countries 发展中国家疫苗接种运动的一些问题
Vaccination research : open journal Pub Date : 2016-12-31 DOI: 10.17140/vroj-1-e001
Chengjun Sun
{"title":"Some Problems of Vaccination Campaigns in Developing Countries","authors":"Chengjun Sun","doi":"10.17140/vroj-1-e001","DOIUrl":"https://doi.org/10.17140/vroj-1-e001","url":null,"abstract":"Vaccination offers the most cost-effective approach to prevent and control infectious diseases in the history of mankind.1 The English physician Edward Jenner introduced smallpox vaccine in 1798. It is the first successful vaccine to be developed. Since then a series of vaccines have been developed and come into use; for example, the influenza vaccine, the hepatitis B vaccine, and the polio vaccine. The World Health Organization (WHO) reports that licensed vaccines are currently available to successfully combat against twenty-five infections.2","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74067609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herd Immunity Conferred By Hepatitis B Vaccination Increases the Protection Efficacy against Hepatitis B Virus Infection 接种乙型肝炎疫苗后的群体免疫增强了对乙型肝炎病毒感染的保护作用
Vaccination research : open journal Pub Date : 2016-12-31 DOI: 10.17140/vroj-1-103
Yuting Wang, Ling-ling Lu, Dongmei Wang, C. Qu
{"title":"Herd Immunity Conferred By Hepatitis B Vaccination Increases the Protection Efficacy against Hepatitis B Virus Infection","authors":"Yuting Wang, Ling-ling Lu, Dongmei Wang, C. Qu","doi":"10.17140/vroj-1-103","DOIUrl":"https://doi.org/10.17140/vroj-1-103","url":null,"abstract":"Most of the chronic infections with Hepatitis B Virus (HBV) are acquired in perinatal period or in early life in China. We conducted HBV serosurveys in the same community among the age 5-6 year old children who were born in 1979-1980, in 1985-1986, and in 2002-2003, respectively. The seropositive rate of HBV surface antigen (HBsAg) was 11.43% in the unvaccinated population. It decreased to 2.08% among the vaccinated children born in the same year. With increased vaccination coverage the HBsAg seropositive rate decreased to 0.24% among the age 6-7 year old children born in 2002-2003, with 98.21% protection efficacy. Herd immunity conferred by HBV vaccination increases the protection efficacy against HBV infection.","PeriodicalId":93237,"journal":{"name":"Vaccination research : open journal","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85895972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信